Detecting iron levels in diseased cells for better treatment options
Developing a pretargeting strategy to detect Fe(II) for nuclear medicine applications
This study is looking at a new way to measure iron levels in cells, especially in areas affected by disease, which could help doctors better understand and treat conditions related to iron imbalances.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10809007 on NIH RePORTER |
What this research studies
This research focuses on developing a new method to measure ferrous iron (Fe2+) levels in cells, particularly in diseased tissues. By utilizing a specialized compound that can bind to iron, the researchers aim to visualize and quantify iron concentrations in living organisms. This approach could help in understanding how altered iron metabolism relates to various diseases and may lead to improved therapies that target these conditions. Patients may benefit from more accurate diagnostics and tailored treatments based on their specific iron metabolism.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with conditions that involve abnormal iron levels, such as certain cancers or degenerative diseases.
Not a fit: Patients with normal iron metabolism or those not affected by diseases related to iron dysregulation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for diseases associated with altered iron metabolism.
How similar studies have performed: Previous research has shown promise in using similar approaches to target and treat diseases by exploiting altered iron metabolism, indicating potential for success in this novel application.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Evans, Michael John — University of California, San Francisco
- Study coordinator: Evans, Michael John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.